These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 28455961)

  • 1. Repositioning chlorpromazine for treating chemoresistant glioma through the inhibition of cytochrome c oxidase bearing the COX4-1 regulatory subunit.
    Oliva CR; Zhang W; Langford C; Suto MJ; Griguer CE
    Oncotarget; 2017 Jun; 8(23):37568-37583. PubMed ID: 28455961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of Small Molecule Inhibitors of Human Cytochrome c Oxidase That Target Chemoresistant Glioma Cells.
    Oliva CR; Markert T; Ross LJ; White EL; Rasmussen L; Zhang W; Everts M; Moellering DR; Bailey SM; Suto MJ; Griguer CE
    J Biol Chem; 2016 Nov; 291(46):24188-24199. PubMed ID: 27679486
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nuclear-encoded cytochrome c oxidase subunit 4 regulates BMI1 expression and determines proliferative capacity of high-grade gliomas.
    Oliva CR; Markert T; Gillespie GY; Griguer CE
    Oncotarget; 2015 Feb; 6(6):4330-44. PubMed ID: 25726526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
    Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
    Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel drug conjugate, NEO212, targeting proneural and mesenchymal subtypes of patient-derived glioma cancer stem cells.
    Jhaveri N; Agasse F; Armstrong D; Peng L; Commins D; Wang W; Rosenstein-Sisson R; Vaikari VP; Santiago SV; Santos T; Chen L; Schönthal AH; Chen TC; Hofman FM
    Cancer Lett; 2016 Feb; 371(2):240-50. PubMed ID: 26683773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acquisition of chemoresistance in gliomas is associated with increased mitochondrial coupling and decreased ROS production.
    Oliva CR; Moellering DR; Gillespie GY; Griguer CE
    PLoS One; 2011; 6(9):e24665. PubMed ID: 21931801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytochrome c oxidase mediates labile iron level and radioresistance in glioblastoma.
    Ali MY; Oliva CR; Flor S; Goswami PC; Griguer CE
    Free Radic Biol Med; 2022 May; 185():25-35. PubMed ID: 35476930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monoamine oxidase A (MAO A) inhibitors decrease glioma progression.
    Kushal S; Wang W; Vaikari VP; Kota R; Chen K; Yeh TS; Jhaveri N; Groshen SL; Olenyuk BZ; Chen TC; Hofman FM; Shih JC
    Oncotarget; 2016 Mar; 7(12):13842-53. PubMed ID: 26871599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biological basis and clinical study of glycogen synthase kinase- 3β-targeted therapy by drug repositioning for glioblastoma.
    Furuta T; Sabit H; Dong Y; Miyashita K; Kinoshita M; Uchiyama N; Hayashi Y; Hayashi Y; Minamoto T; Nakada M
    Oncotarget; 2017 Apr; 8(14):22811-22824. PubMed ID: 28423558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of a side population of astrocytoma cells in response to temozolomide.
    Chua C; Zaiden N; Chong KH; See SJ; Wong MC; Ang BT; Tang C
    J Neurosurg; 2008 Nov; 109(5):856-66. PubMed ID: 18976075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of DNA-repair genes Ercc1 and Mgmt enhances temozolomide efficacy in gliomas treatment: a pre-clinical study.
    Boccard SG; Marand SV; Geraci S; Pycroft L; Berger FR; Pelletier LA
    Oncotarget; 2015 Oct; 6(30):29456-68. PubMed ID: 26336131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of an anti-viral drug, Ribavirin, as an anti-glioblastoma therapeutic.
    Volpin F; Casaos J; Sesen J; Mangraviti A; Choi J; Gorelick N; Frikeche J; Lott T; Felder R; Scotland SJ; Eisinger-Mathason TSK; Brem H; Tyler B; Skuli N
    Oncogene; 2017 May; 36(21):3037-3047. PubMed ID: 27941882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide-responsive and -resistant glioblastoma.
    Barone TA; Burkhart CA; Safina A; Haderski G; Gurova KV; Purmal AA; Gudkov AV; Plunkett RJ
    Neuro Oncol; 2017 Feb; 19(2):186-196. PubMed ID: 27370399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NRF2 and glutathione are key resistance mediators to temozolomide in glioma and melanoma cells.
    Rocha CR; Kajitani GS; Quinet A; Fortunato RS; Menck CF
    Oncotarget; 2016 Jul; 7(30):48081-48092. PubMed ID: 27344172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p53 upregulated modulator of apoptosis sensitizes drug-resistant U251 glioblastoma stem cells to temozolomide through enhanced apoptosis.
    Miao W; Liu X; Wang H; Fan Y; Lian S; Yang X; Wang X; Guo G; Li Q; Wang S
    Mol Med Rep; 2015 Jun; 11(6):4165-73. PubMed ID: 25625235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Humanized chondroitinase ABC sensitizes glioblastoma cells to temozolomide.
    Jaime-Ramirez AC; Dmitrieva N; Yoo JY; Banasavadi-Siddegowda Y; Zhang J; Relation T; Bolyard C; Wojton J; Kaur B
    J Gene Med; 2017 Mar; 19(3):. PubMed ID: 28087981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of GSH synthesis potentiates temozolomide-induced bystander effect in glioblastoma.
    Kohsaka S; Takahashi K; Wang L; Tanino M; Kimura T; Nishihara H; Tanaka S
    Cancer Lett; 2013 Apr; 331(1):68-75. PubMed ID: 23246370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Promoting oligodendroglial-oriented differentiation of glioma stem cell: a repurposing of quetiapine for the treatment of malignant glioma.
    Wang Y; Huang N; Li H; Liu S; Chen X; Yu S; Wu N; Bian XW; Shen HY; Li C; Xiao L
    Oncotarget; 2017 Jun; 8(23):37511-37524. PubMed ID: 28415586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. β-Asarone promotes Temozolomide's entry into glioma cells and decreases the expression of P-glycoprotein and MDR1.
    Wang N; Zhang Q; Ning B; Luo L; Fang Y
    Biomed Pharmacother; 2017 Jun; 90():368-374. PubMed ID: 28380412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metformin and temozolomide act synergistically to inhibit growth of glioma cells and glioma stem cells in vitro and in vivo.
    Yu Z; Zhao G; Xie G; Zhao L; Chen Y; Yu H; Zhang Z; Li C; Li Y
    Oncotarget; 2015 Oct; 6(32):32930-43. PubMed ID: 26431379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.